Granules India Limited · NSE:GRANULES
Granules India — Q3 FY2024 Earnings Presentation
23 slides from Granules India's earnings presentation, Jan 23, 2024
Slide 1: Cover letter to stock exchanges
© GRANULES REGISTERED OFFICE GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, Telangana, India. Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com CIN: L24110TG1991PLC012471 Date: January 23, 2024 To, National Stock Exchang
Slide 2: Granules India Limited Earnings Presentation Q3FY24
Granules India Limited Earnings Presentation Q3FY24
Slide 3: Safe harbour
Safe harbour The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any
Slide 4: Key Business Updates
Key Business Updates ▪ Strong performance in the quarter which is reflected in the improved EBITDA margin Performance ▪ US formulations volumes have grown, led by both existing and new products ▪ LATAM business has shown some recovery as compared to the previous quarter ▪ ANDA Approval for Sildenafi
Slide 5: Medicine with near Net Zero Carbon footprint
▪ Identified and finalized two sites at Vizag (12 Acres) and at Kakinada (100 Acres) ▪ Phase I at Vizag: ▪ DCDA pilot plant – Projected completion: Q4 FY24 ▪ PAP – Projected completion: End of FY25 Medicine with near Net ▪ Phase II at Kakinada: Project work expected to start in Kakinada in FY 25. Ze
Slide 6: Q3FY24: Y-o-Y performance highlights – P&L
Q3FY24: Y-o-Y performance highlights – P&L (In ₹ Mn) Q3 FY24 Q3 FY23 Y-o-Y Gr% Y-o-Y performance Volumes growth was higher as compared to value growth. Revenue 11,556 11,461 1% Sales in the US region grew well, led by both existing and new products VA% has improved primarily on account of better pro
Slide 7: Q3FY24: Q-o-Q performance highlights – P&L
Q3FY24: Q-o-Q performance highlights – P&L (In ₹ Mn) Q3 FY24 Q2 FY24 Q-o-Q Gr% Q-o-Q performance Revenue 11,556 11,895 (3%) Revenue is down primarily because of reduction in prices of Paracetamol across all regions. Value Added 6,583 6,144 VA% is significantly better due to better product mix 7% (in
Slide 8: Q3FY24: Revenue split by market
Q3FY24: Revenue split by market (In ₹ Mn) Region wise share Q3 Q3 Y-o-Y Q2 Q-o-Q FY24 FY23 Gr% FY24 Gr% 63% North 64% 7,601 6,268 21% 7,989 (5%) America 49% Europe 2,279 2,728 (16%) 2,128 7% 20% LATAM 587 968 (39%) 429 37% 24% 18% 8% 6% 7% 6% 6% 6% India 701 763 (8%) 673 4% 3% 5% 4% 5% 4% 3% USA Can
Slide 9: Q3FY24: Revenue split by division
Q3FY24: Revenue split by division (In ₹ Mn) Division wise share Q3 Q3 Y-o-Y Q2 Q-o-Q FY24 FY23 Gr% FY24 Gr% 66% 62% API 2,212 4,106 (46%) 3,021 (27%) 46% 36% PFI 1,686 2,130 (21%) 1,457 16% 25% 19% 19% 15% 12% FD 7,658 5,224 47% 7,417 3% API PFI FD Q3 FY24 % Q3 FY23 % Q2 FY24 % ➢ Y-o-Y decline in AP
Slide 10: Q3FY24: Cashflow metrics and Ratios
Q3FY24: Cashflow metrics and Ratios (In ₹ Mn) Q3 FY24 Q2 FY23 Q3 FY24 Q2 FY24 Q3 FY24 Q2 FY24 Fixed Net debt/ ROCE% 15.3% 12.8% asset turn 1.78 1.75 EBITDA 1.16x 1.41x ROCE% improved QoQ because of Higher asset turns are primarily on improvement in EBIT due to increase in account of increase in annu
Slide 11: Last 5 years performance: Sales and profitability
Last 5 years performance: Sales and profitability (In ₹ Mn) Sales: 5yr CAGR: 22% VA and VA%: 5yr CAGR: 23% 45,119 22,046 37,649 18,463 18,813 51% 32,375 47% 45% 13,177 57% 25,986 50% 49% 22,792 10,236 16,918 7,955 FY18 FY19 FY20 FY21 FY22 FY23 FY18 FY19 FY20 FY21 FY22 FY23 EBITDA and EBITDA%: 5yr CA
Slide 12: Last 5 years performance: Cashflow and ratios
Last 5 years performance: Cashflow and ratios (In ₹ Mn) ROCE% Asset turns Net debt and Net debt/EBITDA 28.6% 8,704 9,082 2.00 1.98 2.02 2.06 7,671 1.89 6,966 21.1% 1.75 2.36 6,058 5,752 19.3% 3.13 17.4% 13.1% 1.15 0.97 11.4% 0.67 0.84 FY18 FY19 FY20 FY21 FY22 FY23 FY18 FY19 FY20 FY21 FY22 FY23 FY18
Slide 13: ANDA and Dossier Filing status
ANDA and Dossier Filing status GPI IP GIL IP Filing Status Others (SA, Belarus, Total USA USA Europe Canada UK Isreal & India) Approved 26 62 8 6 3 2 81 Tentatively Approved 1 2 - - - - 2 To be approved 3 8 1 0 7 - 16 Total Products 30 72 9 6 10 2 99 ANDA/Dossier filed - Therapeutic area wise CNS 21
Slide 14: Strategic Priorities and Organizational Transformation
Strategic Priorities and Organizational Transformation
Slide 15: Our Purpose, Vision & Values
Our Purpose, Vision & Values Q) Challenging Limits through pioneering @) Futuristic Thinking green science ©) Empowering Employees @) Customer Driven To establish ourselves as a world leader in green chemical and ©) Quality Everywhere pharmaceutical industry by harnessing cutting-edge technologies t
Slide 16: Strategic Priorities
Strategic. Priorities
Slide 17: Strengthening the core: Building & sustaining our competitive advantage
Strengthening the core Building & sustaining our competitive advantage Manufacturing Excellence Backward integration Process Innovation and KSMs and advanced improvements intermediates Scale & Large Volume MUPS Capacity & Global Leadership in Controlled Substances Core Molecules facilities 16
Slide 18: Strengthening the core: Our manufacturing network & capabilities
Strengthening the core Our manufacturing network & capabilities Bonthapally Jeedimetla Bonthapally II Vizag (Unit 4) Vizag (Unit 5) API: 4,800 TPA API (Intermediate): API: 15 KL PA API: 34,560 TPA API: 380 KL PA PFI: 1,440 TPA 61.5 KL PA FD: 1.1 Bn Gagillapur Virginia, USA GPAK, USA FD: 26.8 Bn 2 OT
Slide 19: R&D and Innovation: Expanding capabilities
R&D and Innovation: Expanding capabilities Strengthened headcount to ̴ 300 across spectrum of R&D centers with complementary capabilities (In ₹ Mn) Integrated Product Development 1,424 1,002 1,164 Genome Valley – MN Park 722 789 R&D facility for Integrated Product Development 525 3% 3% 3% 3% 4% 3% ▪
Slide 20: Sustainability at Granules
Sustainability at Granules One Planet. One Purpose. Embracing green science. 0! Ee) GRANULES CZRG Building our flagship green pharmaceu tical
Slide 21: R&D and Innovation: Becoming an innovation and science-led enterprise
R&D and Innovation: Becoming an innovation and science-led enterprise 20
Slide 22: Demonstrating action against a shared commitment
Demonstrating action against a shared commitment 21
Slide 23: Corporate address and investor relations contacts
Mr. Puneet Varshney GM Business Finance and Head Investor Relations Email: puneet.varshney@granulesindia.com www.granulesindia.com Ms. Payal Dave payal.dave@linkintime.co.in Mr. Irfan Raeen +91 97737 78669 Irfan.raeen@linkintime.co.in www.orientcap.com 532482 GRANULES Corporate address: GRAN:IN Floo